We guide biopharma, diagnostics, and medtech clients through a rapidly changing environment of increasingly customized care that encompasses multiple treatment modalities. Though our understanding of both cancer biology and the realities of clinical practice, we enable our clients to realize larger commercial opportunities through thoughtful clinical development, positioning, and pricing strategies.
Combining our deep technical expertise with long-standing industry experience enables us to advise clients on how to prepare their novel technologies for the market. Our clients were among the first to develop immuno-oncology technologies including autologous cell therapies, virotherapies, and gene-based therapies. We’ve been pioneers in the application of personalized medicine and companion diagnostics to oncology, as well as the use of advanced devices such as the latest radiotherapy technologies. We regularly advise clients on development strategies that include combination-based targeted therapies, state-of-the-art diagnostic methods including next-generation sequencing (NGS), and the emerging convergence of devices, diagnostics, and therapeutics.
We help our clients overcome specific technical, logistical, and clinical challenges, and develop unique and tailored solutions required to bring their products to market. As technologies move closer to the clinic, we assist with challenges such as pricing, market access, and commercial launch. We anticipate challenges products may face in the future to help our clients make effective decisions today.
Vivek Mittal: “When a biotech client needed to understand the low treatment rate for NSCLC, Health Advances used a patient journey approach to identify key barriers to treatment, highlighting those that the client could influence versus those that were out of its control. The client team was then able to develop new messaging and educational campaigns to target some of the key barriers.”
Andrew Funderburk: “We often help clients optimize their development approach by combining insights from mechanistic and scientific analysis, clinical design input from top KOLs, and detailed market understanding, such as in this recent project.”
Gary Gustavsen: “With targeted therapeutics dominating the oncology pipeline, companion diagnostics have been a key focus for our practice. We recently completed a large project for a major biopharma that further validated the need for a globally-orchestrated, but locally-tailored companion diagnostic strategy. The barriers to CDx adoption across markets are unique; every country needs its own set of tactics.”
View our Oncology case examples.